Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study
Semaglutid-Injektion bei indischen Patient:innen mit Typ-2-Diabetes mellitus: randomisierte Phase-III-Studie mit aktiver Kontrolle
Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 7094-7103
DOI: 10.1111/dom.70891 ↗Auf einen Blick
Bei indischen Erwachsenen mit Typ-2-Diabetes war die synthetische Semaglutid-Injektion der Referenz-Semaglutid-Injektion hinsichtlich der HbA1c-Senkung nach 24 Wochen nicht unterlegen. Die Sicherheit war vergleichbar.
Fragestellung
Ist die synthetische Semaglutid-Injektion bei indischen Patient:innen mit Typ-2-Diabetes der Referenz-Semaglutid-Injektion nicht unterlegen?
Methode
Phase-III-Studie, randomisiert, offen, multizentrisch, parallelgruppig, aktiv-kontrolliert, Nichtunterlegenheitsstudie; 35 Zentren in Indien; 24 Wochen Behandlung.
Ergebnisse
314 Patient:innen randomisiert, 290 beendeten die Studie. HbA1c nach 24 Wochen: Test −2,04 %, Referenz −1,95 %; LS-Mittelwertdifferenz −0,09 % (95 %-KI −0,26 bis 0,09), Nichtunterlegenheit erreicht. Häufigste unerwünschte Ereignisse waren gastrointestinale Ereignisse.
Schlussfolgerung der Autor:innen
Die synthetische Semaglutid-Injektion zeigte eine nicht unterlegene glykämische Wirksamkeit und eine vergleichbare Sicherheit gegenüber der Referenz-Semaglutid-Injektion.
Kernaussagen
- HbA1c-Reduktion nach 24 Wochen vergleichbar
- LS-Mittelwertdifferenz −0,09 % (95 %-KI −0,26 bis 0,09)
- Häufigste unerwünschte Ereignisse: gastrointestinale Ereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 31.05.2026. Verfasst von Unnikrishnan Ambika Gopalakrishnan und 33 weiteren Autor:innen. Beteiligte Einrichtung: Chellaram Diabetes Institute, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sun Pharmaceutical Industries Limited, Sun Pharma.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To evaluate the efficacy, safety and immunogenicity of semaglutide injection (synthetic) (Test group) compared with the Reference semaglutide injection [Ozempic, (Reference group)] in Indian patients with Type 2 diabetes mellitus (T2DM). Materials and Methods This Phase III, randomised, open‐label, multi‐centre, parallel‐group, active‐controlled non‐inferiority study was conducted across 35 centres in India. Adults aged 18–65 years with T2DM and baseline glycated haemoglobin (HbA1c) ≥ 7.0% to ≤ 10.5% despite stable metformin therapy and diet & exercise control were randomised (1:1) to receive subcutaneous injections of Test semaglutide or Reference semaglutide once weekly for 24 weeks, using an identical dose‐escalation regimen (from 0.25 to 2.0 mg per week). The primary endpoint was change in HbA1c from baseline to Week 24. Secondary endpoints included changes in fasting and post‐prandial blood glucose, bodyweight and HbA1c < 7.0% achievers, safety and immunogenicity.
Results
A total of 314 patients were randomised, and 290 patients completed the study. At Week 24, both treatments produced significant and comparable reductions in HbA1c (Test: −2.04%, Reference: −1.95%; p < 0.0001 within groups). The least‐squares mean difference (Test‐Reference) was −0.09% (95% CI: −0.26 to 0.09), meeting the pre‐specified non‐inferiority criterion. Improvements in fasting and post‐prandial blood glucose, patients achieving HbA1c < 7.0% and bodyweight were similar between the two groups. The most common treatment‐emergent adverse events were predominantly mild‐to‐moderate gastrointestinal events (Test vs. Reference: 43.3% vs. 46.5%). No anti‐drug or neutralising antibodies were detected.
Conclusions
The Test synthetic semaglutide injection demonstrated non‐inferior glycaemic efficacy, comparable safety in comparison to Reference semaglutide, supporting its use as an effective therapeutic option for patients with T2DM. Prospectively registered on the Clinical Trials Registry—India, CTRI/2025/02/080592 [Registered on: 14/02/2025], URL: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTIwODUw&Enc=&userName= .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chellaram Diabetes Institute, Pune, Maharashtra, India.
- Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India.
- GSVM Medical College, Kanpur, Uttar Pradesh, India.
- Ratan Multi-Speciality Hospital, Ahmedabad, Gujarat, India.
- Motilal Nehru Medical College, Prayagraj, Uttar Pradesh, India.
- Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India.
ORCID-Profile: Shweta Bhandari, Dipesh Sonawane, Dipak Patil
Förderung
- Sun Pharmaceutical Industries Limited
- Sun Pharma
Zitieren
APA
Ambika Gopalakrishnan, U., Joshi, A. S., Giri, R., Shah, S. J., Shukla, J., Maheshwari, S., M Chowdaiah, R., Singh, M. K., Bari, A. S., Pathak, N. P., Shah, A. N., Bhandari, S., Gowda, A., Chandrappa, A., Supe, P. D., Das, B., Sharma, P. K., Virani, M. K., Kurmi, P. H., …, & Mehta, S. (2026). Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study. Diabetes, Obesity and Metabolism, 28(8), 7094-7103. https://doi.org/10.1111/dom.70891
Vancouver
Ambika Gopalakrishnan U, Joshi AS, Giri R, Shah SJ, Shukla J, Maheshwari S, et al. Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study. Diabetes, Obesity and Metabolism. 2026;28(8):7094-7103. doi:10.1111/dom.70891
BibTeX
@article{AmbikaGopalakrishnan2026,
author = {Ambika Gopalakrishnan, Unnikrishnan and Joshi, Ameya Sudhakar and Giri, Richa and Shah, Shalin Jagdeep and Shukla, Jitendra and Maheshwari, Sanjiv and M Chowdaiah, Rekha and Singh, Manish Kumar and Bari, Aditya Srirang and Pathak, Niranjan Pandurang and Shah, Akash Nitinbhai and Bhandari, Shweta and Gowda, Ambanna and Chandrappa, Ambrish and Supe, Pravin Dinkar and Das, Bharat and Sharma, Prabhat Kumar and Virani, Mehul Kalubhai and Kurmi, Prakash Harishchandra and Ghanekar, Gayatri Amit and Dasari, Mani Deepathi and Sahoo, Banshidhar and Jangid, Sanjay Kumar and Shende, Prakash Sadashiv and Patil, Sandesh Sahebarao and Kumbhar, Avinash Narayan and Deshpande, Shrikant Vishnu and Chennappa, Madhusudhan and Patel, Nitesh Chandubhai and Sonawane, Dipesh and Patil, Dipak and Pandit, Sucheta and Ghadge, Pravin and Mehta, Suyog},
title = {Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {8},
pages = {7094--7103},
doi = {10.1111/dom.70891}
}
EUVIMED